Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity

Current Hypertension Reports

Volumn 4, Issue 4, 2002, Pages 261-264

  Ruilope, Luis M ^a   Coca, Antonio ^b   Banegas, José R ^b   Pablos, Jose Luis ^b   Luque, Manuel ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; MORBIDITY; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; HUMANS; MORBIDITY;

EID: 0036689962     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0001-3     Document Type: Note

References (26)

1. Vane JR, Botting RM: Anti-inflamatory drugs and their mechanism of action. Inflamm Res 1998, 47(Suppl 2): S78-S87.
2. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990, 265: 16737-16740.
3. McAdam BF, Mardini IA, Habib A, et al.: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000, 10 5: 1473-1482.
4. Wight NJ, Gottesdiener K, Garlick NM, et al.: Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 2001, 120: 867-873.
5. Van Hecken A, Schwartz JI, Depre M, et al.: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000, 40: 1109-1120.
6. Singh G, Triadafilopoulos G: Epidemiology of NSAIDs induced gastrointestinal complications. J Rheumatol 1999, 26(suppl 56): 18-24.
7. Garcia Rodriguez L, Hernandez-Diaz S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001, 3: 98-101.
8. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354: 2106-2111.
9. Ehrich EW, Schnitzer TJ, McIlwain H, et al.: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol 1999, 26: 2438.
10. Fitzgerald GA, Patrono C: Drug therapy: the coxibs, selective inhibitors of cyclooxigenase-2. N Engl J Med 2001, 345: 433-442.
11. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343: 1520-1528.
12. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroideal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000, 284: 1247-1255.
13. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286: 954-959.
14. Food and Drug Administration: Acessible at http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3677b2-06-cardio.pdf.
15. MacMahon S, Neal B: Differences between blood pressure lowering drugs. Lancet 2000, 356: 352-353.
16. Blood Pressure Lowering Trialist Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 355: 1955-1964.
17. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338: 645-652.
18. Schrier RW, Estacio RO: Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 2000, 343: 1969.
19. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mrtality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356: 366-372.
20. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356: 359-365.
21. Wällberg-Jonsson S, Johansson H, Öhman ML, Rantapää- Dahlqvist S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999, 26: 2562-2571.
22. Knijff-Dutmer EA, Martens A, Laar MA: Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. Ann Rheum Dis 1999, 58: 257-259.
23. Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104: 2280-2288.
24. Antiplatelet Trialists Collaboration: Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308: 81-106.
25. Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2 selective inhibitors. Am J Nephrol 2001, 21: 1-15.
26. Patrono C, Coller B, Dalen JE, et al.: Platelet-active drugs. The relationships among dose, effectiveness and side effects. Chest 2001, 119: 39S-63S.